VERACYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.2 USD | +1.80% |
|
-7.38% | -30.21% |
| Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
| Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Financials (USD)
| Sales 2024 * | 398M | Sales 2025 * | 443M | Capitalization | 1.42B |
|---|---|---|---|---|---|
| Net income 2024 * | -17M | Net income 2025 * | -3M | EV / Sales 2024 * | 3 x |
| Net cash position 2024 * | 220M | Net cash position 2025 * | 267M | EV / Sales 2025 * | 2.59 x |
| P/E ratio 2024 * |
-80
x | P/E ratio 2025 * |
-461
x | Employees | 815 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Veracyte, Inc.
More recommendations
More press releases
| 1 day | +1.80% | ||
| 1 week | -7.38% | ||
| Current month | -13.36% | ||
| 1 month | -11.03% | ||
| 3 months | -24.85% | ||
| 6 months | -7.47% | ||
| Current year | -30.21% |
1 week
18.61
20.24
1 month
18.6122.35
Current year
18.6129.16
1 year
18.6130.52
3 years
14.8554.13
5 years
13.9086.03
10 years
4.2186.03
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Stapley
CEO | Chief Executive Officer | 54 | 21-05-31 |
Rebecca Chambers
DFI | Director of Finance/CFO | 46 | 21-07-18 |
Steven French
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Evan Jones
BRD | Director/Board Member | 67 | 08-01-31 |
Robert Epstein
CHM | Chairman | 69 | 15-01-11 |
Karin Eastham
BRD | Director/Board Member | 74 | 12-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 19.2 | +1.80% | 813,915 |
| 24-04-17 | 18.86 | -0.32% | 656,372 |
| 24-04-16 | 18.92 | -2.32% | 682,622 |
| 24-04-15 | 19.37 | -4.25% | 828,930 |
| 24-04-12 | 20.23 | -2.41% | 563,132 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Calendar
2024-04-29
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
18.86
USD
Average target price
30.83
USD
Spread / Average Target
+63.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.21% | 1.42B | |
| -14.19% | 11.48B | |
| +44.16% | 3.3B | |
| -19.90% | 2.01B | |
| -38.37% | 1.99B | |
| +16.18% | 1.02B | |
| -6.11% | 699M | |
| -32.75% | 429M | |
| -52.35% | 354M | |
| -3.18% | 259M |
- Stock Market
- Equities
- VCYT Stock
